AstraZeneca China

AstraZeneca China

Brief company and industry description
AstraZeneca China — a subsidiary of the global pharmaceutical group AstraZeneca plc, operating in the Chinese market in the field of development, manufacturing and commercialization of prescription drugs, biological medicines and vaccines.

Main products/services and key markets

• Drugs for oncology, cardio-renal metabolism, respiratory and rare diseases.
• Research and development of new medicines, collaboration with Chinese biotech companies.
• Key market — China, where the company is deeply involved in R&D infrastructure and manufacturing.

Year of establishment, revenue, number of employees, presence by country

• Present in China since 1993.
• Total group revenue in 2024 was approximately 54.1 billion USD.
• In China, workforce growth is expected to reach ~1,700 employees as part of a new R&D center.
• Presence: China serves as the company's second most important market after the United States.

What makes their office/plant/production interesting, what can be seen and understood about the business

• A new global strategic R&D center in Beijing, including AI and data laboratories and joint vaccine manufacturing with Chinese partners, reflects the depth of the company's integration into the Chinese ecosystem.
• A visit to the center will allow you to see how a global pharmaceutical group uses local scientific talent and infrastructure to develop world-class medicines.